Moolec Science (MLECW) Free Cash Flow (2022 - 2024)
Moolec Science (MLECW) posted Free Cash Flow of $1.9 million for Q4 2024, up 280.89% sequentially from -$1.1 million in Q3 2024, and down 13.22% YoY from $2.2 million in Q1 2024.
Moolec Science (MLECW) Free Cash Flow (2022 - 2024) Analysis & Trends
Moolec Science has reported Free Cash Flow for 3 years, with the latest figure at $1.9 million in Q4 2024.
- Quarterly Free Cash Flow fell 13.22% year-over-year to $1.9 million in Q4 2024, while the trailing twelve-month figure through Mar 2026 was $1.9 million (changed N/A YoY) and the FY2025 annual result came in at -$2.0 million, down 106.8% from the prior year.
- Free Cash Flow rose to $1.9 million in Q4 2024 per MLECW's latest filing, from -$1.1 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $37.8 million in Q2 2024 and troughed at -$47.8 million in Q2 2023.
- A 3-year average of -$1.4 million and a median of -$524097.0 in 2022 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 287.68% in 2023, down 17089.24% in 2023.
- Over 3 years, Free Cash Flow stood at $573367.0 in 2022, then jumped by 287.68% to $2.2 million in 2023, then fell by 13.22% to $1.9 million in 2024.
- According to Business Quant data, Free Cash Flow over the past three periods registered $1.9 million, -$1.1 million, and $37.8 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.93 Mn |
| Dec 31, 2024 | 1.93 Mn |
| Sep 30, 2024 | -1.07 Mn |
| Sep 30, 2024 | -1.07 Mn |
| Jun 30, 2024 | 37.78 Mn |
| Jun 30, 2024 | 37.78 Mn |
| Mar 31, 2024 | -2.61 Mn |
| Mar 31, 2024 | -2.61 Mn |
| Dec 31, 2023 | 2.22 Mn |
| Dec 31, 2023 | 2.22 Mn |
| Sep 30, 2023 | -1.64 Mn |
| Sep 30, 2023 | -1.64 Mn |
| Jun 30, 2023 | -47.81 Mn |
| Jun 30, 2023 | -47.81 Mn |
| Mar 31, 2023 | -5.43 Mn |
| Mar 31, 2023 | -5.43 Mn |
| Dec 31, 2022 | 573,367.00 |
| Dec 31, 2022 | 573,367.00 |
| Sep 30, 2022 | 9,648.00 |
| Sep 30, 2022 | 9,648.00 |